Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06605404 · ClinicalTrials.gov registry record

Pan-tumor MRD Study

A clinical trial of Esophageal Cancer and NSCLC (Non-small Cell Lung Cancer), sponsored by Paradigm Health.

Recruiting
Registry status
1,350
Enrollment target
2
Study locations

NCT06605404: Recruiting study of Esophageal Cancer and NSCLC (Non-small Cell Lung Cancer), sponsored by Paradigm Health.

NCT06605404 is a study of Esophageal Cancer and NSCLC (Non-small Cell Lung Cancer) that is actively recruiting participants, run by Paradigm Health. The registered enrollment target is 1,350 participants, above the 488-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (177% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06605404, a study of Esophageal Cancer and NSCLC (Non-small Cell Lung Cancer), is actively recruiting participants, sponsored by Paradigm Health.

RECRUITING
Registry status
1,350 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Primary Outcome

To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

Conditions Studied

Esophageal Cancer NSCLC (Non-small Cell Lung Cancer) Melanoma (Skin Cancer) Muscle Invasive Bladder Urothelial Carcinoma Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Pancreatic (Exocrine Only) Mix of Solid Tumors (MOST)

Interventions

  • DIAGNOSTIC_TEST blood and tissue samples
  • OTHER blood and tissue samples

Study Locations (2)

California

  • Medical Oncology Associates of San Diego - San Diego

Ohio

  • Taylor Cancer Research Center - Maumee

Trial Details

FieldValue
Enrollment Target 1,350 participants
Start Date 2025-01-08
Est. Completion 2032-04
Paradigm Health

1 total trials

What NCT06605404 shows while recruiting

NCT06605404 is an observational study that tracks outcomes without assigning an intervention. Its 1,350 participants enrollment target places it among the larger protocols in the corpus, above the 488-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (177% higher).

The record links to 7 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which blood and tissue samples is the first listed.

NCT06605404 reports a single indexed study location in California, Ohio.

Frequently Asked Questions

What is clinical trial NCT06605404 about?

NCT06605404 is a clinical study titled "Pan-tumor MRD Study". The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, fo...

What is the current status of trial NCT06605404?

This trial is currently recruiting. The enrollment target is 1,350 participants. The study started on 2025-01-08. Estimated completion is 2032-04.

What conditions does trial NCT06605404 study?

This clinical trial studies the following conditions: Esophageal Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer), Muscle Invasive Bladder Urothelial Carcinoma, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma.

What interventions are being tested in trial NCT06605404?

The interventions under investigation include: blood and tissue samples (DIAGNOSTIC_TEST), blood and tissue samples (OTHER).

Who is sponsoring clinical trial NCT06605404?

This trial is sponsored by Paradigm Health, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06605404 being conducted?

This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Esophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06605404's enrollment target sits among peer trials

1,350 11th of 123 higher than 113 of 123 other Esophageal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06318169 · 1,350 participants · Phase 3

    A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  • NCT06806163 · 1,350 participants · NA

    Machine-Learning Prediction and Reducing Overdoses With EHR Nudges

  • NCT06731608 · 1,344 participants · NA

    OsteoPorotic fracTure preventION System (OPTIONS) Research Study

  • NCT05245227 · 1,358 participants · Phase 3

    Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06605404

Source: ClinicalTrials.gov NCT06605404, the US trial registry maintained by the National Library of Medicine. NCT06605404 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.